In vivo chimeric antigen receptor (CAR)-T cell therapy
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-10-01 07:59
摘要：
In vivo chimeric antigen receptor (CAR)-T cell therapy represents a transformative approach in treating hematological malignancies and autoimmune diseases. This innovative method generates CAR-T cells directly within the patient's body, eliminating the need for complex ex vivo processing. Recent advancements in RNA delivery systems and viral vectors have shown promising results in early clinical studies, demonstrating efficient transduction and initial antitumor activity. This strategy not only enhances the scalability and safety of CAR-T therapies but also broadens their applicability beyond blood cancers.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
1.0
关键证据
In vivo CAR-T cell engineering seeks to overcome challenges of traditional methods.
Recent advances in virology and RNA medicines have catalyzed this approach.
Early clinical studies have shown efficient transduction and sustained CAR expression.
真实性检查
否
AI评分总结
In vivo chimeric antigen receptor (CAR)-T cell therapy represents a transformative approach in treating hematological malignancies and autoimmune diseases. This innovative method generates CAR-T cells directly within the patient's body, eliminating the need for complex ex vivo processing. Recent advancements in RNA delivery systems and viral vectors have shown promising results in early clinical studies, demonstrating efficient transduction and initial antitumor activity. This strategy not only enhances the scalability and safety of CAR-T therapies but also broadens their applicability beyond blood cancers.